From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
|Articles|February 14, 2023
Suneel Chilukuri, MD, Shares Details on Hydrinity's New Skin Care Line
Author(s)Carrie Nagorka, Senior Editor
The main ingredients in Hydrinity Accelerated Skin Science's new line of products are hyaluronic acid and peptides.
Advertisement
For more information on Hydrinity Accelerated Skin Science's new line of products, go to
Advertisement
Related to this article
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5